Vcanbio Cell & Gene Engineering (600645) Stock Overview
Engages in the preparation and storage of cell detection tests in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600645 from our risk checks.
600645 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Vcanbio Cell & Gene Engineering Corp., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.02 |
| 52 Week High | CN¥32.99 |
| 52 Week Low | CN¥16.24 |
| Beta | -0.16 |
| 1 Month Change | -9.40% |
| 3 Month Change | -3.74% |
| 1 Year Change | -28.52% |
| 3 Year Change | 2.85% |
| 5 Year Change | -17.98% |
| Change since IPO | 591.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600645 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -0.1% | 0.6% |
| 1Y | -28.5% | -24.1% | 3.8% |
Return vs Industry: 600645 underperformed the CN Biotechs industry which returned -24.1% over the past year.
Return vs Market: 600645 underperformed the CN Market which returned 3.8% over the past year.
Price Volatility
| 600645 volatility | |
|---|---|
| 600645 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600645 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600645's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,935 | Hongqi Wang | www.vcanbio.com |
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, children and adults, disease inheritance, and disease susceptibility; and in vitro diagnostic raw materials such as monoclonal antibodies and polyclonal antibody products, and the research, development, production and sales of Class I, Class II and Class III in vitro diagnostic reagents and medical devices.
Vcanbio Cell & Gene Engineering Corp., Ltd Fundamentals Summary
| 600645 fundamental statistics | |
|---|---|
| Market cap | CN¥8.22b |
| Earnings (TTM) | CN¥117.11m |
| Revenue (TTM) | CN¥1.40b |
Is 600645 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600645 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.40b |
| Cost of Revenue | CN¥419.35m |
| Gross Profit | CN¥978.60m |
| Other Expenses | CN¥861.49m |
| Earnings | CN¥117.11m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 70.00% |
| Net Profit Margin | 8.38% |
| Debt/Equity Ratio | 0.7% |
How did 600645 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 16:47 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vcanbio Cell & Gene Engineering Corp., Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ye Hui Yang | Huatai Research |
| Ban Wang | Minsheng Securities Co. |
| Tao Fu | Topsperity Securities |